管线
PIPELINE
浙江足球赌注软件以满足临床需求为导向来开发自己拥有全球知识产权的高质量化合物。
1：NHWD-870 晚期癌症研究进展，目前在临床二期。
2：WD-890 银屑病关节炎，红斑狼疮，肠炎等适应症，目前在临床一期。
3: WD-910 多发性硬化症，痴呆症。
4：WD-920 渐冻症，帕金森。
5：WD-930 肿瘤。
6：WD-940 肿瘤。
Zhejiang Wenda develops its own high-quality compounds with global intellectual property.
1. NHWD-870 Advanced cancer, in the second phase trial.
2. WD-890 Indications such as psoriatic arthritis, lupus erythematosus and enteritis, etc, in the first phase trial .
3. WD-910 Multiple sclerosis, dementia
4. WD-920 ALS, Parkinson's disease.
5. WD-930 Advanced cancer.
6: WD-940 Advanced cancer.
| 项目名称/代号 | 靶点 | 适应症 | 研究进展 | NDA | |||||
|---|---|---|---|---|---|---|---|---|---|
| 化合物筛选 | 临床前 | IND | I期 | II期 | III期 | ||||
| NHWD-870 | BET抑制剂 | 中线癌(NUT) | |||||||
| 非霍奇金淋巴瘤 | |||||||||
| WD-890 | TYK2(JH2)抑制剂 | 红斑狼疮、银屑病、关节炎 | |||||||
| WD-910 | NA | 多发性硬化症，痴呆症 | |||||||
| WD-920 | NA | 渐冻症，帕金森 | |||||||
| WD-930 | NA | 肿瘤 | |||||||
| WD-940 | NA | HER2/HER2 20ins突变型肿瘤 | |||||||
NHWD-870: BET 抑制剂
NHWD-870: BET 抑制剂同类产品全球进展最快的是 CPI0610，骨髓纤维化的国际多中心（149个）三期临床
ZEN3694加标准疗法联用用于前列腺癌、三阴性乳腺癌、其它多种晚期肿瘤在二期临床
NHWD-870是国内进展最快，表现最好的产品CPI0610, an international multi-centers (149) Phase III clinical product of myelofibrosis, is the product with the fastest progress in the world
ZEN3694 is used in combination with standard therapy for prostate cancer, triple negative breast cancer, and a variety of other advanced tumors in phase II
NHWD-870 is the fastest-growing and best-performing product in China (Phase II clinical trial is going on).溴结构域（BRD）和超末端家族蛋白（BET）抑制剂，导致溴结构域蛋白（BRD4）与癌基因MYC增强剂解离，下调MYC基因的表达，从而抑制癌细胞增殖.
Bromodomain (BRD) and super terminal family protein (BET) inhibitors, resulting in the dissociation of bromodomain protein (BRD4) from oncogene MYC enhancer, down-regulate MYC gene expression, thereby inhibiting cancer cell proliferation.
肺癌、非霍奇金氏淋巴瘤等.
Lung cancer, non-Hodgkin's lymphoma, etc.
WD-890: TYK2 抑制剂
WD-890: TYK2 抑制剂我们的WD-890在改构策略上和BMS相近，且临床前研究也取得类似结果，因此WD-890也将在TYK2抑制剂的多种适应症上获准上市，成为一个大药。
中国虽有三家企业进入竞争赛道，但以WD-890的结构差异化、工艺技术，可以通过临床的考验，获得成功.
BMS986165 has been approved by FDA for marketing in psoriasis, psoriatic arthritis is expected to be marketed next year.
WD-890 is similar to BMS in remodeling strategy, and similar results have been obtained in preclinical studies. WD-890 will also be approved for marketing in multiple indications and becomes a blockbuster drug.
创新靶向药物，阻断 JAK/STAT 通路，抑制与免疫反应有关的炎症发生。
Innovative targeted drugs block the JAK/STAT pathway and inhibit the occurrence of inflammation related to immune response.
1. 盘状及系统性红斑狼疮
2. 银屑病（牛皮癣）、银屑病关节炎
3. 溃疡性结肠炎
1. Discoid and systemic lupus erythematosus
2. Psoriasis, psoriatic arthritis
3. Ulcerative colitis
WD-910: 透脑抑制剂
WD-910: 透脑抑制剂多发性硬化症, 阿尔茨海默病，WD-910抑制剂具有良好的有效性，没有明显的副作用的特点，在银屑病领域的成功预示着在脑中枢神经炎症系统也有巨大的应用前景。
Multiple sclerosis, Alzheimer's disease WD-910 has the characteristics of good effectiveness and no obvious side effects. The success in the field of psoriasis indicates that WD-910 also has great application in the central nervous system.
多发性硬化症、老年痴呆
Multiple sclerosis and Alzheimer's disease
WD-920: 透脑的高选择性抑制剂
WD-920: 透脑的高选择性抑制剂
通过血脑屏障治疗脑部疾病，且避免对细胞和骨髓的损害，可望成为全球第一个该领域的化合物大量
研究表明，抑制剂能够抑制多种炎症，如肠炎、肝炎、神经炎症，并在心血管疾病、肺动脉
高压、脑出血、帕金森、老年痴呆等重大疾病中发挥作用. WD-920来研究脑卒中这个世界重大疾病
Treating brain diseases through blood-brain barrier and avoiding damage to cells and bone marrow is expected to become the first large number of compounds in this field in the world.
Studies have shown that inhibitors can inhibit a variety of inflammations, such as enteritis, hepatitis and neuritis, and are effective in cardiovascular diseases, pulmonary artery.
Hypertension, cerebral hemorrhage, Parkinson's disease, Alzheimer's disease and other major diseases. WD-920 to study stroke, a major disease in the world.
WD-930：透脑的高选择性抑制剂
WD-930：透脑的高选择性抑制剂WD-940: 透脑的突变抑制剂
WD-940: 透脑的突变抑制剂上市产品为乳腺癌高表达抑制剂，对突变型乳腺瘤及其它癌种无效，且伴有严重的皮肤搔痒，及胃肠道副作用。
现有BI1810631刚进入一期临床，NVL-330，ENVL-002，BMS尚在临床前研究，预期WD-940在2024年进入临床，加入国际大竞争。
The product on the market is a high expression inhibitor of breast cancer, which is ineffective for mutant breast adenoma and other cancers, accompanied by severe skin itching and gastrointestinal side effects.
The existing BI1810631 has just entered the first phase of clinical practice, while NVL-330 ENVL-002 and BMS are still under preclinical study. It is expected that WD-940 will enter the clinical practice in 2024 and join the international competition.